CMS is expanding access to GLP-1 weight loss medications for eligible Medicare beneficiaries through a new demonstration program known as the Medicare GLP-1 Bridge Program. The initiative gives qualifying beneficiaries access to certain weight loss medications beginning July 1, 2026, through December 31, 2027.

As interest in GLP-1 medications continues to grow, agents should be prepared to answer questions regarding eligibility, covered drugs, and potential savings.

The Big Picture

For years, access to GLP-1 medications for weight loss has been limited due to high costs and restrictive coverage rules. As a result, Medicare beneficiaries often had few options unless they met specific medical criteria.

The new Medicare GLP-1 Bridge Program creates an opportunity for eligible beneficiaries to access certain medications at a significantly lower cost while CMS evaluates longer-term obesity treatment strategies.

Which GLP-1 Medications Are Covered?

Under the Medicare GLP-1 Bridge Program, CMS currently includes:

• Wegovy® (injection and tablet)
• Zepbound® KwikPen®
• Foundayo®

The program only covers select GLP-1 medications. Agents should encourage clients to verify coverage before beginning treatment.

When Does Coverage Begin?

Eligible Medicare beneficiaries can access covered medications through the program beginning July 1, 2026. The demonstration will continue through December 31, 2027.

The program is designed as a bridge to future obesity management initiatives being considered by CMS.

Who Is Eligible?

Eligibility is based on CMS guidelines and generally requires:

• Enrollment in a Medicare Part D plan
• Meeting certain BMI requirements
• Satisfying clinical criteria related to weight-related health conditions

Coverage determinations will vary by individual circumstances, making it important for beneficiaries to work with their healthcare providers during the qualification process.

Potential Cost Savings for Beneficiaries

One of the most notable aspects of the program is affordability.

CMS indicates that eligible beneficiaries may pay a $50 monthly copay for covered GLP-1 medications obtained through the Medicare GLP-1 Bridge Program.

Considering that many GLP-1 medications can cost hundreds or even thousands of dollars per month without coverage, this program could provide substantial savings for qualifying beneficiaries.

What About Medicaid?

Medicaid participation varies by state, meaning availability and implementation timelines may differ across the country. Beneficiaries enrolled in Medicaid should review state-specific requirements and coverage options.

What This Means For Agents

The growing demand for GLP-1 medications means clients are increasingly looking to their agents for guidance.

Agents should prepare to:

• Understand the basics of GLP-1 coverage under Medicare
• Discuss eligibility requirements with clients
• Direct beneficiaries to healthcare providers for clinical guidance
• Stay informed about future CMS updates and obesity treatment initiatives

With expanded coverage now available for many beneficiaries, GLP-1 medications are likely to become an increasingly important topic during Medicare conversations and annual plan reviews.